secwatch.observer — SEC 8-K summary
======================================

Issuer:     ALUMIS INC. (ALMS)
CIK:        0001847367
Form:       8-K
Filed at:   2026-08-10T20:06:06+00:00
Accession:  0001104659-26-093353
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Envudeucitinib achieves 54% PASI 100 at 48 weeks; NDA on track for 4Q 2026
--------------------------------------------------------------------------

- 54% of patients achieved PASI 100 (complete skin clearance) at 48 weeks; 75% achieved PASI 90.
- Integrated analysis (890 pts) showed 66% PASI 90 and 47% PASI 100 at 48 weeks.
- 1,509 patients rolled into ONWARD3 from ONWARD1/2 (>85% rollover); safety consistent, no new signals.
- NDA submission to FDA planned for 4Q 2026; LUMUS Phase 2b SLE topline expected 3Q 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1847367/000110465926093353/0001104659-26-093353-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1847367/000110465926093353/tm2622655d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-093353

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer